Target intelligence / Profile preview

Alpha-1,3-mannosyltransferase (ALG3) (ALG3)

Target
ALG3
Molecular classification
Enzyme, Glycosyltransferase, LLO (lipid-linked oligosaccharide) assembly enzyme
01

Overview

Alpha-1,3-mannosyltransferase (ALG3) is an enzyme located in the endoplasmic reticulum membrane, where it plays an essential role in protein N-glycosylation by transferring the sixth of nine mannose residues from dolichol-phosphate mannose to the lipid-linked oligosaccharide precursor. This step is crucial for the correct assembly of the dolichol-linked oligosaccharide, which is later transferred en bloc to nascent proteins. Mutations in the ALG3 gene cause congenital disorder of glycosylation type Id (ALG3-CDG), an autosomal recessive multisystem disorder marked by neurodevelopmental delay, dysmorphic features, visual impairment, and currently without specific treatment. Diagnosis can be supported by specific glycoform and oligosaccharide biomarker patterns, but is confirmed genetically[1][2][3].

Other names
Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferaseDol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferaseAsparagine-linked glycosylation protein 3 homologNot56-like proteinNOT56LNot56CDGS4D16Ertd36eCarbohydrate deficient glycoprotein syndrome type IVDolichyl-phosphate-mannose--glycolipid alpha-mannosyltransferaseCDG1DCDGS6NOTnotMannosyltransferase 6 deficiencyAsparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-1,3-mannosyltransferase)EC 2.4.1.258EC 2.4.1.130
02

Biological functions

N-linked protein glycosylationTransfer of mannose residues to growing oligosaccharide chainsAssembly of lipid-linked oligosaccharide precursors in the endoplasmic reticulumPrecursor formation for protein N-glycosylation
03

Disease associations

Inherited metabolic disorder (congenital disorder of glycosylation, specifically CDG type Id/ALG3-CDG)Neurological diseaseCongenital malformation syndromesVisual/ophthalmological disorders
04

Safety considerations

No approved therapies; main challenge is multisystemic phenotype with severe neurodevelopmental impairment and failure to thriveDiagnostic challenge as symptoms may overlap with other congenital glycosylation disorders
05

Biomarkers

Serum and fibroblast levels of Man0-4GlcNAc2 (elevated in ALG3 deficiency)Transferrin glycoform analysis (type 1 pattern by isoelectric focusing/mass spec)

Beyond the preview

Go deeper on Alpha-1,3-mannosyltransferase (ALG3) (ALG3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-1,3-mannosyltransferase (ALG3) (ALG3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call